Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adam Kesner

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
European Journal of Nuclear Medicine and Molecular Imaging|June 3, 2021
New PET technologies - embracing progress and pushing the limitsNicolas Aide, Charline Lasnon, Adam Kesner, et al.
European Journal of Radiology|December 2, 2025
Safety and efficacy of Yttrium-90 transarterial radioembolization of neuroendocrine liver metastasis - A retrospective single-institution studyGavin Yuan, Elena N Petre, Harry Marquis, et al.
Physics in Medicine and Biology|February 25, 2026
The UF/MSK pediatric mesh-based computational human phantom library: applications to organ dosimetry in computed tomographyJared Baggett, Robert J Dawson, Laura Dinwiddie, et al.
Journal of Vascular and Interventional Radiology : JVIR|May 18, 2023
Yttrium-90 Activity Quantification in PET/CT-Guided Biopsy Specimens from Colorectal Hepatic Metastases Immediately after Transarterial Radioembolization Using Micro-CT and AutoradiographyNicola Naydenov, Alexei Teplov, Mahdi Zadeh Zirakchian, et al.
Medrxiv : the Preprint Server for Health Sciences|January 23, 2024
First-in-human imaging with [<sup>89</sup>Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumors of the lung and prostateSalomon Tendler, Mark P Dunphy, Matthew Agee, et al.
The Lancet. Oncology|July 1, 2024
Imaging with [<sup>89</sup>Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: a phase 1/2, first-in-human trialSalomon Tendler, Mark P Dunphy, Matthew Agee, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
European Journal of Nuclear Medicine and Molecular Imaging|June 3, 2021
New PET technologies - embracing progress and pushing the limitsNicolas Aide, Charline Lasnon, Adam Kesner, et al.
European Journal of Radiology|December 2, 2025
Safety and efficacy of Yttrium-90 transarterial radioembolization of neuroendocrine liver metastasis - A retrospective single-institution studyGavin Yuan, Elena N Petre, Harry Marquis, et al.
Physics in Medicine and Biology|February 25, 2026
The UF/MSK pediatric mesh-based computational human phantom library: applications to organ dosimetry in computed tomographyJared Baggett, Robert J Dawson, Laura Dinwiddie, et al.
Journal of Vascular and Interventional Radiology : JVIR|May 18, 2023
Yttrium-90 Activity Quantification in PET/CT-Guided Biopsy Specimens from Colorectal Hepatic Metastases Immediately after Transarterial Radioembolization Using Micro-CT and AutoradiographyNicola Naydenov, Alexei Teplov, Mahdi Zadeh Zirakchian, et al.
Medrxiv : the Preprint Server for Health Sciences|January 23, 2024
First-in-human imaging with [<sup>89</sup>Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumors of the lung and prostateSalomon Tendler, Mark P Dunphy, Matthew Agee, et al.
The Lancet. Oncology|July 1, 2024
Imaging with [<sup>89</sup>Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: a phase 1/2, first-in-human trialSalomon Tendler, Mark P Dunphy, Matthew Agee, et al.
Pageof 2